Display options
Cite
Takahara T, Sugiyama K, Zhang LP, et al. Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepatol Res. 2004;28(3):146-154doi: 10.1016/j.hepres.2003.11.003.
Takahara, T., Sugiyama, K., Zhang, L. P., Ando, O., Fujii, M., Yata, Y., Bo, J., Xue, F., Minemura, M., & Watanabe, A. (2004). Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepatology research : the official journal of the Japan Society of Hepatology, 28(3), 146-154. https://doi.org/10.1016/j.hepres.2003.11.003
Takahara, Terumi, et al. "Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model." Hepatology research : the official journal of the Japan Society of Hepatology vol. 28,3 (2004): 146-154. doi: https://doi.org/10.1016/j.hepres.2003.11.003
Takahara T, Sugiyama K, Zhang LP, Ando O, Fujii M, Yata Y, Bo J, Xue F, Minemura M, Watanabe A. Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepatol Res. 2004 Mar;28(3):146-154. doi: 10.1016/j.hepres.2003.11.003. PMID: 15036071.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2004 Mar;28(3):146-154. doi: 10.1016/j.hepres.2003.11.003.

Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model.

Hepatology research : the official journal of the Japan Society of Hepatology

Terumi Takahara, Kota Sugiyama, Li Ping Zhang, Osamu Ando, Mitsukiyo Fujii, Yutaka Yata, Jin Bo, Feng Xue, Masami Minemura, Akiharu Watanabe

Affiliations

  1. Third Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama City, Toyama, 930-0194, Japan.

PMID: 15036071 DOI: 10.1016/j.hepres.2003.11.003

Abstract

Background/Aims: Interferon-alpha is used widely to treat viral hepatitis. Interferon-gamma modulates a system attacking infected cells and also has an anti-fibrotic effect. A treatment with interferon-alpha and -gamma has undergone trials in eliminating hepatitis C virus. We investigated effects of cotreatment in a liver fibrosis model to explore anti-fibrotic effects. Methods: Rats were assigned to groups including normal controls (NC), CCl(4) controls, rat interferon-alpha treatment, rat interferon-gamma treatment, and cotreatment. All groups except normal controls received CCl(4) orally for 8 weeks. At the beginning of the third week of exposure, 6 weeks of treatment were initiated according to interferon group. Digitally analyzed immunohistochemistry, biochemical assays, and Northern analysis were performed. Results: Pixels (x10(5)) per field containing immunoreactive type III collagen (fibrotic density) in CCl(4) controls, interferon-alpha, interferon-gamma, and cotreatment groups respectively were [Formula: see text], [Formula: see text], [Formula: see text] and [Formula: see text]. Liver hydroxyproline content correlated with fibrotic density, and was significantly low in the cotreatment group. Plasma hyaluronate and transaminase were significantly low in cotreatment and interferon-alpha groups. Northern blotting showed lowest mRNA expression for type I collagen, desmin, transforming growth factor (TGF)-beta1, and matrix metalloproteinase-2 mRNA in the cotreatment group; tissue inhibitor of metalloproteinase-1 and -2 mRNAs were significantly low in the interferon-gamma group. Conclusions: Cotreatment can suppress collagen and transforming growth factor-beta1 and has an overall anti-fibrotic effect without exacerbating inflammation.

Publication Types